Farid's career has focused on researching and developing monoclonal antibodies to cell and gene therapies. She was appointed a lecturer at UCL in 2001 after completing her PhD there.[1] In 2007 Farid's paper discussing the cost-effective manufacture of antibodies was published in the Journal of Chromatography .[2]
She featured in Biotechnology and Bioengineering in 2012, with Farid evaluating current and future potential of batch and continuous cell culture technologies. The paper followed a case study into the commercial manufacture of monoclonal antibodies.[3]
In 2020 Farid and lead-author Maria Papathanasiou published a paper in Nature on how T cells could be used as a cancer therapy in the future.[4][5] Her expertise in the field led her to be part of the government task force during the COVID-19 pandemic as a member of the 100 Days Mission roundtable. Farid was also interviewed numerous times in relation to the development of a vaccine and also became Director of the UCL-AstraZeneca Bioprocessing Centre of Excellence.[6]
In 2022 she was elected a fellow of the Royal Academy of Engineering. [7][8] She is also co-director of the Future Targeted Healthcare Manufacturing Hub, which is funded by the Engineering and Physical Sciences Research Council.[9]
